Study published in Int. J. Mol. Sci. on the efficacy of Mesenchymal stromal cell/stem cell small extracellular vesicles (MSC-sEV) in STAM™
SMC is proud to announce that Agency for Science, Technology and Research (A*STAR) (SGP) has published the results of their study using our pre-clinical services with the STAM™ model in Int. J. Mol. Sci.
Title
MSC−sEV Treatment Polarizes Pro−Fibrotic M2 Macrophages without Exacerbating Liver Fibrosis in NASH
(Zhang et al., Int J Mol Sci., 2023)
In this study, the efficacy of mesenchymal stromal cell/stem cell small extracellular vesicles (MSC-sEV) in the treatment of NASH is being evaluated.
Authors show that compared to STAM™ mice in the vehicle-treated group, NASH-phase STAM™ mice treated with MSC-sEV had significantly lower NAFLD activity score (the main clinical endpoint for evaluating fatty liver) and fibrosis area in the liver. These Results suggest that MSC-sEV may be useful in the treatment of NASH.
The STAM™ mouse is the world's first pathological mouse model to show the progression of NASH to liver cancer, and was developed here at SMC Laboratories. This model shows a similar pathology to human NASH (steatosis → NASH → liver fibrosis → HCC). Therefore, the STAM™ model has been used in many efficacy studies, as well as in basic research.
We would also be happy to arrange a Zoom meeting with our marketing and science team to briefly explain what services we offer and how we might be able to support your project.
If you are interested in using our STAM™ model, please do not hesitate to reach out!
Thank you for your time, and we look forward to the opportunity to work with you.